long-acting cabotegravir/rilpivirine

(CAB LA/RPV LA)

DHHS recommendation not yet established
Long-Acting Regimen

Standard Dose

Clinical trials of this investigational regimen used a long-acting cabotegravir injection of 400 mg plus 600 mg rilpivirine injection every 4 or 8 weeks. The dose consisted of two 2 mL injections. Oral rilpivirine must be taken with food; the injectable does not. An induction phase with oral medication was used in research and will be used when approved. The cabotegravir tablet may not otherwise be available on the market.

Manufacturer

ViiV Healthcare
viivhealthcare.com
(877) 844-8872

AWP

Not yet established.

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments